PIK3CD
ENSG00000171608
Target class
Enzyme
Chromosome
1
Approved drugs
7
Clinical candidates (approved and in development)
46
- Approved drugs
- 7
- ClinGen gene-disease validity
- Definitive
- Clinical candidates (approved and in development)
- 46
- Chemical probe available
- Yes
- Other names
- p110D
- Target name
- PIK3CD
- Gene name
- Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit delta
- Gene symbol
- PIK3CD
- Protein name
- Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit delta isoform (PI3-kinase subunit delta) (PI3K-delta) (PI3Kdelta) (PtdIns-3-kinase subunit delta) (EC 2.7.1.137) (EC 2.7.1.153) (Phosphatidylinositol 4,5-bisphosphate 3-kinase 110 kDa catalytic subunit delta) (PtdIns-3-kinase subunit p110-delta) (p110delta)
- Gene biotype
- Protein coding
- Gene family
- Phosphatidylinositol 3-kinase family
- Target class
- Enzyme
- Target type
- Human gene
- Tissues expressed in
- 53
- Protein localisation evidence grade
- Approved
- Highest tissue expression
- 111.7
- Tissue specificity (Gini)
- 0.534
- Tissue specificity (tau)
- 0.903
- KEGG gene identifiers
- hsa:5293
- Protein interaction confidence
- 0.901383
- Protein interaction partners
- 133
- R-HSA-1257604
- R-HSA-1660499
- R-HSA-2219530
- R-HSA-389357
- R-HSA-512988
- R-HSA-6811558
- R-HSA-8853659
- R-HSA-9027276
- R-HSA-912526
- R-HSA-912631
- R-HSA-9680350
- R-HSA-983695
- R-HSA-9856530
- R-HSA-9927354
- End position
- 9730117
- Start position
- 9629889
- Chromosome
- 1
- Strand
- Forward
- Cytoplasm .
- Cytokinetic bridge
- Cytosol
- Microtubules
- Primary cilium
- Primary cilium tip
- Vesicles
Publication evidence
- PubMed 22020336
- Tissue specificity (tau)
- 0.903299
- Expression inequality (Gini)
- 0.533512
Expression in transcripts per million
- Cells - EBV-transformed lymphocytes
- 111.7
- Whole Blood
- 96.7
- Spleen
- 83.94
- Lung
- 23.99
- Small Intestine - Terminal Ileum
- 15.74
Expression in transcripts per million
- Cells - EBV-transformed lymphocytes111.7
- Whole Blood96.7
- Spleen83.94
- Lung23.99
- Small Intestine - Terminal Ileum15.74
- Ovary14.49
- Cervix - Endocervix14.08
- Uterus12.36
- Fallopian Tube12.2
- Adipose - Visceral (Omentum)11.47
- Thyroid11.17
- Bladder10.94
- Cervix - Ectocervix10.6
- Artery - Aorta10.51
- Nerve - Tibial10.45
- Vagina10.25
- Artery - Coronary9.79
- Esophagus - Muscularis9.65
- Artery - Tibial9.42
- Colon - Sigmoid9.41
- Testis9.41
- Esophagus - Gastroesophageal Junction9.29
- Adipose - Subcutaneous9.18
- Kidney - Medulla8.88
- Prostate8.7
And 29 more, listed on the interactive page.
- GO:0001779
- GO:0001819
- GO:0001938
- GO:0002250
- GO:0002551
- GO:0002679
- GO:0006954
- GO:0010595
- GO:0010628
- GO:0010818
- GO:0030101
- GO:0030217
- GO:0030335
- GO:0030593
- GO:0031295
- GO:0033031
- GO:0035747
- GO:0035754
- GO:0038084
- GO:0042110
- GO:0042113
- GO:0043303
- GO:0043491
- GO:0045087
- GO:0050852
And 4 more, listed on the interactive page.
- GO:0005829
- GO:0005886
- GO:0005515
- GO:0016303
- GO:0046934
Related records
Trials (513)
- (CHANT)Real World Study of Duvelisib in the Treatment of Non-Hodgkin's Lymphoma (NHL)
- 1630GCC: Zydelig Maintenance in B-Cell Non-Hodgkin's Lymphoma After Autologous Stem Cell Transplantation
- 5G-PEARL: Paxalisib in Malignant Brain Tumours
- A 3-Part Study to Determine the Relative Bioavailability of Capsule and Tablet Formulations of GDC-0980, the Effect of Food, and the Effect of Rabeprazole on the Pharmacokinetics of the Tablet
- A Bioavailability and Pharmacokinetic Study of GDC-0032 in Healthy Volunteers
- A Clinical Study of Novel Pneumococcal Vaccine V118C in Children (V118C-002)
- A Clinical Trial of Buparlisib and Ibrutinib in Lymphoma
- A Dose Escalation Study Evaluating the Safety and Tolerability of GDC-0032 in Participants With Locally Advanced or Metastatic Solid Tumors or Non-Hodgkin's Lymphoma (NHL) and in Combination With Endocrine Therapy in Locally Advanced or Metastatic Hormone Receptor-Positive Breast Cancer
- A Dose-escalation Study to Assess the Safety, Tolerability, and Pharmacokinetics of GDC-0032 in Combination With Docetaxel or With Paclitaxel in Patients With HER2-negative Locally Recurrent or Metastatic Breast Cancer or Non-small Cell Lung Cancer
- A Double-Blind Study Evaluating Duvelisib in Subjects With Moderate to Severe Rheumatoid Arthritis and an Inadequate Response to Methotrexate Alone
- A Drug Interaction Study of GDC-0032 Co-administered With Rifampin or Itraconazole in Healthy Volunteers
- A Long-term, Continued Treatment and Follow-up Study in Participants With Hematologic Malignancies Treated With Duvelisib (IPI-145)
- A Multicenter Phase I/II Trial of Abiraterone Acetate + BEZ235 in Metastatic, Castration-Resistant Prostate Cancer
- A Pharmacokinetics Study to Assess Abiraterone Acetate Capsule and Tablet Formulations in Patients With Prostate Cancer
- A Phase 1 Dose Escalation Study of VS-5584 Administered in Combination With VS-6063, in Subjects With Relapsed Malignant Mesothelioma
- A Phase 1 Study of Duvelisib in Patients With Advanced Hematologic Malignancies
- A Phase 1/2, Open-Label, Dose Escalation, Safety and Tolerability Study of INCB050465 and Itacitinib in Subjects With Previously Treated B-Cell Malignancies (CITADEL-101)
- A Phase 1b Study Evaluating GS-9820 in Subjects With Lymphoid Malignancies
- A Phase 1b/2 Study of IPI-145 Plus FCR in Previously Untreated, Younger Patients With CLL
- A Phase 2 Safety and Efficacy Study of INCB050465 in Subjects With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (CITADEL-202)
Drugs (50)
- Acalisib PI3-kinase p110-delta subunit inhibitor
- AMG-319 PI3-kinase p110-delta subunit inhibitor
- Apitolisib PI3-kinase class I inhibitor
- AZD-6482 PI3-kinase class I inhibitor
- AZD-8186 PI3-kinase p110-delta subunit inhibitor
- BGT-226 PI3-kinase class I inhibitor
- BGT-226 FREE BASE PI3-kinase class I inhibitor
- Buparlisib PI3-kinase class I inhibitor
- CAL-263 PI3-kinase p110-delta subunit inhibitor
- Copanlisib PI3-kinase p110-delta subunit inhibitor
- Copanlisib hydrochloride PI3-kinase p110-delta subunit inhibitor
- Dactolisib PI3-kinase class I inhibitor
- DS-7423 PI3-kinase class I inhibitor
- Duvelisib PI3-kinase p110-delta subunit inhibitor
- Duvelisib monohydrate PI3-kinase p110-delta subunit inhibitor
- Fimepinostat PI3-kinase p110-delta subunit inhibitor
- Gedatolisib PI3-kinase class I inhibitor
- GSK-1059615 PI3-kinase class I inhibitor
- GSK-2269557 PI3-kinase p110-delta subunit inhibitor
- Idelalisib PI3-kinase p110-delta subunit inhibitor